Compare Cytokinetics Inc (CYTK) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs iShares MSCI China ETF — how do they compare? Cytokinetics Inc trades at $75.63 (market cap $10.63B), while iShares MSCI China ETF trades at $55.08. The key difference: Cytokinetics Inc is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals.
| CYTK | MCHI | |
|---|---|---|
Market Cap | $10.63B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $87.26 | $66.99 |
52-Week Low | $34.31 | $50.48 |
Enterprise Value | $10.74B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $76.24, down 1.61% over 24 hours, with a bearish technical signal from moving averages and neutral oscillators. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, while revenue reached $88.04 million in 2025. Despite negative profitability margins, strong analyst sentiment exists with 34 buy ratings and a consensus price target of $111.14, driven by optimism around Myqorzo's commercial uptake and recent UK regulatory approval.
The outlook hinges on Myqorzo's commercial execution and pipeline expansion, offering significant upside if revenue growth accelerates. Key risks include persistent cash burn, high debt-to-asset ratio of 81.23%, and competitive pressures in the cardiovascular drug market. Investors should weigh the high valuation (P/S of 140.65) against the potential for future profitability breakthroughs.
MCHI trades at $55.01, down 3.37% amid broader Chinese stock pressure. Technical indicators show a bullish overall signal with strong moving average support, though oscillators remain neutral. The ETF benefits from China's export strength and AI-driven manufacturing rebound, with exports jumping 23% in July (CNBC, 2026-08-06). Recent institutional activity includes Empowered Funds acquiring $1.47M in shares (Defense World, 2026-08-08).
MCHI presents value opportunity trading at significant discount to US indices, with financial sector benefiting from China's yield curve. Key risks include US-China trade tensions and regulatory uncertainty. The $295B AI infrastructure plan (Bloomberg, 2026-06-09) provides long-term growth catalyst, though near-term volatility persists amid geopolitical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
